Inactive Instrument

Analyst Reco. PharmaCan Capital Corp Toronto S.E.

Equities

MJN

CA7171151094

End-of-day quote Toronto S.E. Other stock markets
- ^CAD	-

May. 28	Cronos Group Ends Sale-Leaseback Deal with Future Farmco, Continues to Explore Options for Peace Naturals Campus	MT
May. 28	Cronos Group Fluctuating in U.S. After Hours As Terminates Sale-Leaseback of Peace Naturals Campus	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CIBC Adjusts Cronos Group Price Target to $3.50 From $3, Maintains Outperform Rating	May. 15	MT
Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	Mar. 22	MT
Bernstein Starts Cronos Group at Market Perform with CA$4.10 Price Target	22-11-02	MT
Barclays Adjusts Cronos Group's Price Target to $3.50 from $5, Maintains Equalweight Rating	22-09-30	MT
Cronos Group Price Target Raised to $7 at Raymond James	22-07-29	MT
CIBC Upgrades Cronos Group to Outperform From Neutral	22-05-12	MT
Raymond James Adjusts Cronos Group Price Target to $6 From $5, Maintains Outperform Rating	22-05-09	MT
Barclays Upgrades Cronos Group to Equalweight From Underweight	22-03-22	MT
Piper Sandler Lowers Cronos Target to US$3 on Cash Flow Outlook, Maintains Neutral Rating	22-03-07	MT
Piper Sandler Adjusts Cronos Group Price Target to $3 From $4, Maintains Neutral Rating	22-03-07	MT
CORRECTION : --Canaccord Genuity Adjusts Cronos Group's Price Target to CA$4.25 from CA$7, Maintains Sell Rating	22-02-22	MT
Canaccord Genuity Adjusts Cronos Group's Price Target to $4.25 from $7, Maintains Sell Rating	22-02-22	MT
Stifel Adjusts Cronos Group's Price Target to $4 From $6.50, Reiterates Hold Rating	22-02-22	MT
Piper Sandler Adjusts Cronos Group's Price Target to $4 From $7, Maintains Neutral Rating	22-02-22	MT
Cronos Group Neutral Rating Reiterated by Piper Sandler Following Q3 Results, Q2 Restatement	22-02-18	MT
Jefferies Upgrades Cronos Group to Hold From Underperform	22-01-27	MT
Cannabis Stocks Brief: Barclays Initiates Underwhelming Ratings on Canada Cannabis Cos Due To Difficulties In Having US Multi-State Operations, Citing Canopy Growth Recent Moves, BNN TV notes	21-11-23	MT
Cronos Brief: Initiated With Underweight Rating and Target of US$5 at Barclays, notes BNN TV	21-11-23	MT
Barclays Starts Cronos Group at Underweight With $5.50 Price Target	21-11-18	MT
Cannabis Brief: BNN Also Notes Sector Expected To Operate At An Annual Run Rate of Near $8-9 Billion Over Next Few Years, "Despite Profitability Challenges"	21-09-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. PharmaCan Capital Corp Toronto S.E.

Equities

MJN

CA7171151094

Analyst Reco.

Filters